OraVital Signs United Kingdom Distribution Agreement
Toronto, CA –OraVital Inc., the Toronto-based developer of the OraVital® System for the diagnosis and treatment of the oral infections that cause periodontal disease, peri-implantitis, halitosis and caries, recently signed a distribution agreement naming Stat Health Group, as its exclusive sales agent in the United Kingdom.
According to OraVital CEO, Jim Hyland, DDS, “We’re very excited to be working with Stat Health Group to help us expand into the United Kingdom. Together, I believe we’ll have a positive impact on controlling oral infections as well as oral-systemic health risks.”
Under the terms of the agreement, Stat Health Group will be responsible for introducing UK dental practices to the OraVital® System and providing them with the necessary training, marketing support and logistical management of OraVital’s biofilm test lab analysis and prescriptive antimicrobial rinses.
“By using the OraVital® System, UK dental professionals can now predictably control the oral infections that cause periodontal disease, halitosis and caries in 90% of their affected patients in just 4 weeks,” explained Stat Health Group CEO Stephen Judge. “Our ultimate goal is to establish The OraVital® System as the new standard of care in the United Kingdom.”